复方苦参注射液在胃肠肿瘤化疗周期初升白细胞作用的临床观察

The clinical observation of Compound Kuhsheng Injection in lencocyte count promotive function for subnormal lencocyte count gastrointestinal cancer patients before the chemotherapy cycle

目的:评价复方苦参注射液在胃肠肿瘤化疗周期初升白细胞作用及疗效。方法:选取167名化疗周期前伴有白细胞下降的胃肠肿瘤患者,分为复方苦参治疗组92例,给予复方苦参注射液治疗,对照组75例给予常规升白细胞治疗,二组进行对照。结果:治疗组升白细胞有效率87.0%,优于对照组,有统计学差异(P<0.05)。结论:对胃肠肿瘤化疗前伴有白细胞下降患者,应用复方苦参注射液可获得较快的提升白细胞能力,同时减轻化疗的毒副作用,提高患者耐受力。

Objective ：To evaluation the therapeutic efficiency of Compound Kuhseng Injection use to promote gastrointestinal cancer patients＇lencocyte count. Methods： 167 subnormal lencoeyte count gastrointestinal cancer patients before the chemotherapy cycle were divided into two group, 92 patients of test group were treated with Compound Kuhseng Injection, and 75 patients of control group only received conventional therapy. Results ：The effective rate of treatment group is 87.0%, surpassing the rate of control group, having statistical significance （ P 〈 0.05）. Conclusions ： For the subnormal lencocyte count gastrointestinal cancer patients before the chemotherapy cycle, the Compound Kuhseng Injection is more efficient to promote the lencocyte count than the control group, reduces the incidence rates of the side effects of chemotherapy apparently, and increases the patients＇tolerance to chemotherapy.